The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.
 
Ana Christina Garrido-Castro
Honoraria - AstraZeneca; Daiichi Sankyo
Consulting or Advisory Role - AstraZeneca; Daiichi-Sankyo; Novartis
Research Funding - 4D Path (Inst); AstraZeneca (Inst); Biovica (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Foundation Medicine (Inst); Gilead Sciences (Inst); Merck (Inst); Novartis (Inst); Precede Bio (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Merck; Novartis; Roche/Genentech
 
Se Eun Kim
No Relationships to Disclose
 
Jennifer Desrosiers
No Relationships to Disclose
 
Rita Nanda
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Exact Sciences; GE Healthcare; Gilead Sciences; Guardant Health; Merck; Moderna Therapeutics; Novartis; Sanofi; Seagen; Stemline Therapeutics
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); OncoSec (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sun Pharma (Inst); Taiho Oncology (Inst)
Other Relationship - G1 Therapeutics
 
Lisa A. Carey
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); NanoString Technologies (Inst); Novartis (Inst); Seagen (Inst); Veracyte (Inst)
(OPTIONAL) Uncompensated Relationships - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly; Novartis (Inst); SeaGen
 
Amy Sanders Clark
Honoraria - Siemens
Consulting or Advisory Role - Novartis
Research Funding - Lilly (Inst); Novartis (Inst); Seagen (Inst)
 
Ruth Lauren Sacks
Stock and Other Ownership Interests - Quest Diagnostics
 
Thomas Patrick O'Connor
No Relationships to Disclose
 
Natalie Faye Sinclair
No Relationships to Disclose
 
K.M. Steve Lo
No Relationships to Disclose
 
Amy Thomas
No Relationships to Disclose
 
Eileen Wrabel
No Relationships to Disclose
 
Tess O'Meara
No Relationships to Disclose
 
Nancy U. Lin
Stock and Other Ownership Interests - Artera
Consulting or Advisory Role - Artera; AstraZeneca; Blueprint Medicines; Daiichi Sankyo; Eisai; Johnson & Johnson/Janssen; Menarini; Olema Pharmaceuticals; Pfizer; Seagen
Research Funding - Genentech (Inst); Merck (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Seagen (Inst); Zion Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for chapter in Up-to-Date regarding management of breast cancer brain metastases; Royalties, Jones & Bartlett
Travel, Accommodations, Expenses - Olema Pharmaceuticals
 
Harold J. Burstein
No Relationships to Disclose
 
Mengni He
No Relationships to Disclose
 
David L. Rimm
Honoraria - Amgen
Consulting or Advisory Role - AstraZeneca; Cell Signaling Technology; Cepheid; Daiichi Sankyo/Astra Zeneca; Danaher; Halda Therapeutics; Incendia; NextCure; PAIGE.AI; Regeneron; Sanofi
Research Funding - Amgen (Inst); Cepheid (Inst); Konica Minolta (Inst); Navigate Biopharma (Inst); NextCure (Inst)
Patents, Royalties, Other Intellectual Property - Quantitative Immunofluorescence (AQUA) (Inst); Rarecyte Circulating tumor cells
 
Elizabeth A. Mittendorf
Honoraria - Physicans' Education Resource
Consulting or Advisory Role - Alight Sciences; AstraZeneca; BioNTech SE; Merck; Moderna Therapeutics
Research Funding - Gilead Sciences (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Merck Sharpe and Dohme
(OPTIONAL) Uncompensated Relationships - Bristol-Myers Squibb; Roche/Genentech
 
Nabihah Tayob
No Relationships to Disclose
 
Sara M. Tolaney
Consulting or Advisory Role - AADi; ARC Therapeutics; Artios Biopharmaceuticals; AstraZeneca; Bayer; BeyondSpring Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb; CytomX Therapeutics; Daiichi Sankyo; eFFECTOR Therapeutics; Eisai; Genentech; Hengrui Pharmaceutical (USA); Immunomedics/Gilead; Incyte; Infinity Pharmaceuticals; Jazz Pharmaceuticals; Lilly; Menarini Group; Merck; Natera; Novartis; OncXerna Therapeutics; Pfizer; Reveal Genomics; Sanofi; Seagen; Sumitovant Biopharma; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis; Zetagen; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Novartis (Inst); OncoPep (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Lilly; Sanofi